Research Seminars

About

Research Seminars gather a small number (20 to 100) of well-established and preferably young investigators to address scientific topics in depth and help break new ground. Research Seminars take place over two days in easy-to-reach European cities. They are scientific Seminars involving recently published work and research in progress. Participation is fully supported by the budget granted by the ERS.

ERS Presidential Summit on Research gaps, patient needs and innovative solutions: a forward look on lung health research

The objective of the Summit is to identify priority research topics that should be addressed at European level. In doing so, we will hear over the coming days from all stakeholders – medical professionals, patients, pharmaceutical industry, research funders and research policymakers. This approach builds on the work of previous Presidential Summits – which saw the European Respiratory Roadmap and a focus on health inequalities providing the background from which to tackle respiratory disease. The outcomes will be valuable to our Society in the coming months – as a basis for focusing our potential scientific and research activities and indeed as a basis for advocacy and discussion with the European Commission.

Download all media

Opening & welcome F. Blasi (Milan, Italy)
Keynote address E. Meehan (Dublin, Ireland)
WHO actions to promote lung health H. Kluge (Copenhagen, Denmark)
Strategic research priority setting for health in Horizon 2020 H. Laverty (Brussels, Belgium)
Health Research collaboration in Europe: an innovative initiative G. Kogan (Brussels, Belgium)
Health priorities during the Lithuanian Presidency A. Veryga (Ministry of Health, Lithuania)
Discussion
Tobacco and the global attack on lung health W. MacNee (Edinburgh, United Kingdom)
From home to the work place: the impact of air quality N. Kuenzli (Basel, Switzerland)
The rising epidemic of social inequalities in Europe I. Annesi-Maesano (Paris, France)
Discussion
Meeting the challenge of AMR and respiratory infections F. Blasi (Milan, Italy), Tobias Welte (Hanover, Germany)
Personalised medicine: a step forward to better care? S. Holgate (Southampton, United Kingdom)
Comorbidities and the ageing lung J. Vestbo (Odense, Denmark)
Mainstreaming research for rare diseases J-P. Sculier (Brussels, Belgium)
Panel discussion: identify concrete areas/topics where collaboration at EU-level is necessary. P.J. Barnes (London, United Kingdom), S. Holgate (Southampton, United Kingdom), K.F. Rabe (Großhansdorf, Germany), T. Welte (Hanover, Germany), J-P. Sculier (Brussels, Belgium), J. Vestbo (Odense, Denmark), B. Flood (Wexford, Ireland)
Key role of patients in clinical trials R. Mccrory (Co Down, Ireland)
Challenge of adherence to treatment in chronic diseases G. Canonica (Genoa, Italy)
Living with a rare disease: LAM patient’s view E. Reilly (Dublin, Ireland)
Living with a rare disease: CF patient’s view K. Murphy (Galway, Ireland)
Living with a rare disease: ELF Patient Ambassador Programme M. Fletcher (Warwick, United Kingdom)
Discussion
Pharma view on public private partnerships G. Recchia (Verona, Italy)
Discussion
Leaders report back to plenary P.J. Barnes (London, United Kingdom), S. Holgate (Southampton, United Kingdom), K.F. Rabe (Großhansdorf, Germany), T. Welte (Hanover, Germany), J-P. Sculier (Brussels, Belgium), J. Vestbo (Odense, Denmark), B. Flood (Wexford, Ireland)